Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPULAR: Posaconazole PK in Haematology
NCT03717623Phase 4Recruiting
- Sponsor
- Melbourne Health
- Start
- Aug 2019
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of posaconazole in invasive fungal infection (IFI), invasive candidiasis and invasive aspergillosis (IA), sponsored by Melbourne Health. Primary endpoint: Pre-dose plasma Posaconazole concentrations at Day 21. Started Aug 2019; status: recruiting.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)invasive candidiasisinvasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT03717623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717623.